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A strong Rand, June heat, a beautiful country, and a fun
and vibrant city — it doesn’t get much better.  Nearly 
20 000 delegates attended the 15th International Aids
Society (IAS) Conference in Thailand.  They came to hear the
latest updates from the scientists, activists and policy-
makers, network with collaborators, sample the local Asian
cuisine, and try to get  ‘One Night in Bangkok’ out of their
heads.
Bangkok is hot, bustling and polluted, with traffic from
hell; it’s also fun, vibrant, friendly and safe, with everything
from glorious developed-world infrastructure, to a strong
sense of culture and vast shopping plazas.  Huge numbers
of Southern African government health officials,
researchers and HIV programme implementers descended
on the city, desperately seeking refuge from an African
winter.
This review of the conference doesn’t do justice to its full
depth or breadth, with around 15 different interest streams
operating concurrently, but I hope it captures a few of the
highlights, especially where southern African researchers
contributed significantly to the programme, or where
research directly informs our situation.
Richard Gere is an unlikely figure to preach safe sex, but
that’s what he did.  The American Gigolo star shared a
platform with Miss Universe 2004 (Australian Jennifer
Hawkins in case you don’t follow these things),
significantly undermining controversial abstinence
programmes, according to many slightly breathless
onlookers.  Add Ashley Judd, Dionne Warwick and Rupert
Everett, and we had a mini-Oscars event.
AIDS conference veteran Madiba, attending his third
consecutive conference, laid down the gauntlet,
emphasising that he had retired but could not rest until he
felt AIDS was being addressed with the urgency it deserved.
‘Please let me enjoy my retirement’, he pleaded with
delegates, 2 days before his 86th birthday. His wife Graca
Machel played an extremely active part throughout the
programme, much to the delight of celebrity watchers.
Peter Piot, the charismatic leader of USAIDS, and 
Richard Feacham, head of the ambitious Global Fund, 
made upbeat presentations, listing strong, new and novel
programmes and partners, and stressing renewed 
commitment from governments and treatment 
partners. However, the UNAIDS data were worrying
(http://www.unaids.org/bangkok2004/report.html),
confirming previous data showing limited impact of
prevention programmes on a regional level in sub-Saharan
Africa, and the disastrous increase in new infections in Asia
and Russia. There was a also strong indication that
prevention programmes were failing in high-risk groups in
developed countries, along with a steady increase in viral
resistance to drugs.
No AIDS conference is complete without a nevirapine (NVP)
public relations crisis imported from South Africa.  The
Minister of Health, popping in to open the South African
stall at the Conference, was reported as announcing the
deregistration of NVP for mother-to-child transmission
(MTCT), with a pointed jibe at activists that this confirmed
her previous view that the drug should never have been
used for MTCT.  NVP resistance post-MTCT was the focus of
a large part of the Conference, and the spat attracted
plenty of international media and research interest.  A
hastily convened press conference chaired by a visibly
W D F Venter, FCP (SA), DTM&H, HIV Man Dip (SA),
Reproductive Health Research Unit, University of the Witwatersrand, Johannesburg
D Wilson, FCP (SA)
Department of Medicine, Edendale Hospital, KwaZulu-Natal,
and Centre for the AIDS Research Programme in South Africa
CONFERENCE REPORT
Thai me up, Thai me down —  The XV
IAS Conference in Bangkok
UNAIDS figures revealed little to celebrate, with big increases
in Asian and Russian numbers.
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weary Zackie Achmat from the Treatment Action Campaign
(TAC), recently nominated for a Nobel Peace Prize, provided
a vibrant debate on the NVP issue, as well as the status of
the national antiretroviral (ARV) roll-out.  Many senior
government health representatives attended the session,
and participated in the discussion.  Eventually, it was
clarified that there was no plan to deregister the drug, and
that the Medicines Control Council (MCC) was simply
recommending against monotherapy with NVP for MTCT, a
position no one could argue with.  Dr Precious Matsotso,
the hard-working head of the MCC, clarified the issue of
deregistration calmly, saying that it was the MCC’s
responsibility and not that of the minister to deregister the
drug.  Other government officials also reassured the
audience that there was no plan to stop the NVP MTCT
implementation programme.  The ideal treatment for MTCT
is highly active antiretroviral therapy (HAART) – NVP
monotherapy acknowledges that we do not have the
human resources or infrastructure to provide HAART to all
pregnant women with HIV in southern Africa. 
The Conference played host to a huge variety of interest
groups, and international governments, pharmaceutical
companies and donors were attacked at many levels for not
doing enough, doing it wrong, or not doing it in a co-
ordinated fashion.  The USA in particular provided a
lightning rod for many perceived wrongs in the HIV world.
One senior journalist bemoaned the fact that he had to
keep apologising for being American:  ‘I feel like a white
South African in the 1980s!’  A diverse group of activists,
researchers and community groups attacked PEPFAR (the
Presidential Emergency Program for AIDS Relief), the huge
HIV relief fund initiated by President George Bush, with
allegations of American protection of multinational
pharmacy patent rights, criticism of the focus on
abstinence and monogamy, and perceptions of  a challenge
to the efficacy  of condoms. Some issues raised by activists
that were not US-related were straight from the headlines,
while other activist issues seemed curious to African
observers – the demand for access to obscure ARVs, the
perceived ethical problems with using tenofovir for
prevention of HIV in sex workers highlighted by Paris
ACTUP, and the strong focus on intravenous drug abusers.
Ugandan President Yoweri Museveni did not help clarify
things, in a peculiar plenary speech that seemed to
undermine condom use and promote a very old-fashioned
view of morality.  The head of PEPFAR, Randall Tobias,
bravely faced a loud group of protestors, and strongly
defended the PEPFAR goals, pointing out that the USA gave
more to AIDS than all the other donor nations combined.
He defended the allocation of one-third of the PEPFAR
prevention budget to abstinence programmes, pointing out
that this approach was successful in Uganda.  He said that
he knew condoms prevented HIV, which he had been
reported as questioning in the past.  The National Institute
of Health (NIH)’s Tony Fauci, who walks on water among
HIV researchers, said that he thought the USA’s approach
was ‘good housekeeping’. This did not stop senior officials,
including UN Secretary General Kofi Annan, French
president Jacques Chirac and Stephen Lewis, special UN
envoy on AIDS in Africa, from criticising the USA on various
fronts, including the fact that PEPFAR limits its support to
only a few affected countries.
For those interested in the political aspects of HIV, it was a
feast.  Other attendees grumpily maintained that the
science was being undermined by the ‘soft’ issues.  HIV
continues to be a showcase for the world’s inequalities and
social challenges, and solutions to these are not
immediately forthcoming.  Science purists may have to give
future conferences a miss.  It’s a messy disease to manage,
and no organiser was going to please the dozens of interest
groups attending.
Developing-world public health workers breathed a huge
sigh of relief as a diminutive investigator (who was later
given an award for excellence at the closing ceremony)
compared the World Health Organisation (WHO)’s 3 by 5
Initiative-recommended drugs with other regimens used in
California (Abstract MoOrB1082).  The WHO recommends
combinations, using nucleoside backbones of stavudine
(d4T) or zidovudine (AZT), with lamivudine (3TC), with either
efavirenz or nevirapine.  The study demonstrated that the
WHO’s choices were the best performers, significantly
outperforming alternative regimens using other
nucleosides and protease inhibitors (PIs) in terms of
survival.  South African adult treaters sat feeling
particularly smug, as the regimen selected for South
Africa’s roll-out as first-line therapy, d4T/3TC and efavirenz,
received the accolade of ‘best on test’.1 However, Harry
Moultrie, Baragwanth Hospital’s paediatric doyen, correctly
pointed out that there was a period where clinicians started
patients who were more ill on PIs, which may actually
explain the survival difference.  The WHO will have to move
fast to achieve its goal of treating 3 million people with
ARVs in the next 18 months, good drug choices or not, as
Jim Kim, head of the WHO’s team tasked with this,
admitted.
The South African Health Minister initiated the MTCT
debate, but hard scientists quickly took centre stage.  The
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WHO released new and widely welcomed guidelines 
at the Conference (http://www.who.int/mediacentre/
releases/2004/pr50/en/). Lynn Morris, from the National
Institute for Communicable Diseases and South Africa’s
leading resistance expert, presented the first long-term
data showing that resistance to non-nucleoside reverse
transcriptase inhibitors (NNRTIs) persisted for up to 6
months in women exposed to NVP single dose (sdNVP),
particularly those with high viral loads and low CD4 counts
(Abstract ThOrB1353).  At the end of the talk she stressed
that this was not a reason to avoid using the drug, and that
the clinical implications of the resistance mutations were
yet to be fully documented.  The much-quoted Thai trials,
showing efficacy of NNRTI-containing regimens in mothers
exposed to NVP MTCT  (presented at the Conference on
Retroviruses and Opportunistic Infections in February
2004) were discussed in a plenary session, and the results
appeared to be less alarming than previously thought.
James McIntyre showed fascinating data in a late breaker
session, demonstrating that adding AZT/3TC for a limited
time after NVP monotherapy could reduce the chances of
NNRTI resistance (Abstract LBOrB09).  Prevention of
maternal transmission began to launch into the downright
peculiar, as breast-feeding grandmothers graced the late
breaker presentation as a way of avoiding exposure to
infected mom’s milk.  
As a separate review of the state of MTCT will be published
in this issue, it will not be covered further here.
The quest for simpler and safer regimens continued, with
exciting and novel approaches to treatments emerging,
challenging the holy grail of ‘triple therapy’.
Kaletra (lopinavir/ritonavir – the ritonavir is used in low
doses (with minimal antiviral effect) to ‘boost’ the blood
levels of the lopinavir) had the sort of glowing reviews we
last saw for efavirenz a year ago at the Paris IAS
Conference.  Kaletra has a resistance barrier that drug
developers dream of.  Data presented at the Conference
showed no resistance to the drug after 5 years of treatment
– patients on regimens containing Kaletra developed
resistance to the other drugs in their regimens, but not to
Kaletra (Abstract WeOrB129).  This is unique in the antiviral
world, where all other drugs exhibit distinct resistance
profiles.  But even resistance to the other drugs was rare in
this study.  As if things couldn’t get any better, it now
appears that we may be able to use the drug once daily, and
the company has applied internationally for QD
registration.  The remaining major concerns with Kaletra
are its ability to cause lipodystrophy, and the fact that it
melts in African heat.
But a Texan dramatically upped the ante (Abstract
MoOrB1057).  In a fascinating and frankly scary
presentation, Dr Gathe from Houston challenged a decade-
long heresy – monotherapy for infected patients.  He
treated 30 patients with Kaletra monotherapy, with CD4
counts from 7 cells/µl to over 400 (average 169 cells/µl),
and many with high viral loads.  Ten fell off for reasons of
toxicity, non-adherence, etc., but 20 had viral loads of
below 400 copies/µl after 48 weeks of treatment.  Eighteen
of these had viral loads below 50.  Commentators flocked
to urge caution, but a new can of worms has been opened
forever. His 24-week data had been greeted at a previous
conference with a ‘wait and see’ attitude.  Now may be the
time to design the big trials that may change the way we
do the business of ARVs.
Other presentations looked at ‘deintensification’, a
treatment concept similar to that used in oncology, where
you use aggressive treatment at the start to contain the
virus, and then once the viral load is low and viral
resistance presumably unlikely, the regimen is simplified to
a single drug.  Patients with undetectable viral loads on
ARVs were randomised to dual therapy with
tenofovir/efavirenz or to the same two drugs plus 3TC.  No
difference between the two arms has yet been seen
(Abstract TuPeB4493), although the trial has not been
completed.  Another used the redoubtable Kaletra as
monotherapy in patients on successful ARVs, with excellent
results (Abstract TuPeB4577).
The meek and mild 3TC still has not had its role as a viral
‘weakener’ clarified.  The unusual M184V mutation
associated with the drug causes the virus to be less ‘fit’,
suggesting a role in deliberately inducing the mutation, by
giving 3TC monotherapy, in a bid to decrease the’
destructive power of the virus.  A small Italian study of
patients failing conventional ARVs showed that people
given monotherapy had slower decreases in CD4 and lower
viral loads than those not given it (Abstract WeOrB1286).
But the bottom line remains — this is an exciting but
completely unconfirmed area.  Do not try this at home!
Several clinicians have used Kaletra as monotherapy locally,
and the evidence to do this is still very dicey – currently it
should not be done outside of a research environment.
Several case reports, the first of which came from
Johannesburg,2 have reported resistance to Kaletra, and
particularly worrying is the occurrence of naturally
resistant mutations in subtype C virus, the most common
clade in southern Africa.
Efavirenz was not to be denied as the ARV poster-child.
Data up to 4 years showed it to be a remarkably effective
as part of a HAART regimen, even in people with high viral
loads, and with very little toxicity (Abstract TuPeB4547).
KALETRA, LAMIVUDINE AND MONOTHERAPY/ DUAL
THERAPY HERESIES
Despite its low resistance barrier, it continues to be an
excellent clinician and patient first choice as part of their
ARV regimen.
It is difficult not to be cynical about the development of
new drugs.  Every HIV conference seems to have dozens of
new candidates paraded, only for them to disappear quietly
off the scene when newly recognised toxicity or poor
efficacy is realised.  However, there were a few interesting
developments.
Reverset (D-D4FC), a new nucleoside, shows excellent
antiviral activity in a presentation given by Midwestern’s
Rob Murphy, with potential to be used in patients with
resistance, and no side-effects in initial studies.  It is now
poised to go to phase 2b studies (MoOrB1056.).  Another PI,
fos-amprenavir, showed good efficacy in people with
multi-drug resistant (MDR) HIV (MoOrB1055).  The much-
awaited chemokine receptor-5 (CCR) blockers had a very
low-key conference (Abstract WePeB5725).
The new PI, atazanavir, continued its cardiovascular darling
status among PIs, with further data that the metabolic
concerns afflicting other PIs are less of an issue with this
drug (Abstracts ThOrB1355, ThOrB1356).  Interestingly,
there were still no data showing that metabolic
consequences translate into clinical events, although one
study showed increased atherosclerosis with PIs compared
with NNRTI-containing regimens (ThOrB1355).  It has
become increasingly apparent that it is not only the PIs
that can cause metabolic problems, and a study (Abstract
ThOrB1360) demonstrated that the (now rarely used)
combination of d4T/didanosine (ddI) causes significant
lipodystophy and metabolic changes previously thought to
be specific to the PIs.  An alarming study showed that
length of time on ARVs correlated with the risk of
eclampsia and fetal death, though reassuringly among the
over 400 women studied there was no MTCT (ThOrB1359).
ARVs seem to spare no organ, and bone came in for a
pasting in a study (Abstract ThOrB1358) demonstrating
convincingly in a multivariate analysis that length of time
on ARVs strongly correlated with the incidence of
osteonecrosis.  Some commentators have noted that HIV-
infected people get a peculiar form of accelerated aging, as
part of their clinical profile – strokes, heart attacks and
crumbly bones are a concern, although still not yet a
clinical reality.
Once-daily dosing of ARVs seems to be the way to go for
the developed world, with much attention being given to a
regimen of combined tenofovir and emtricitabine taken
with efavirenz. HAART delivered by 2 pills taken once daily
was the stuff of dreams 5 years ago, but the surrounding
hype seemed slightly unreal given the ARV access issues in
Africa.
Resistance continued its bogeyman status, with disturbing
data showing resistance occurring in people on ARVs in
three-quarters of patients with viral loads below 1 000
copies/ml (Abstract WeOrB1293.).  But it is unclear how
much clinical panic this should generate, as the gap
between viral resistance and clinical outcomes appears to
be more complex than previously thought.  Studies
treading the boundaries of resistance, using off-on
approaches to ARVs, had variable results, with one trial
having to be stopped because of major resistance.
This area continues its orphan status in the international
HIV conference circuit.  Few presentations dealt with
African experiences of these diseases, although there was
further confirmation that efavirenz 600 mg can be used in
conjunction with conventional rifampicin-containing
tuberculosis (TB) regimens (Abstract MoOrB1013).  Some
clinicians have previously used 800 mg, as some studies
have suggested that efavirenz levels are decreased in
association with rifampicin, but this study showed no
difference in blood levels of efavirenz at the different
doses, and excellent 38-week viral outcomes.
Unfortunately, the study was done in Thais, who are smaller
than people in most other nations, with an average weight
of 50 kg in the study.  Efavirenz’s reputation as a ‘TB-
friendly’ ARV continues, although stronger evidence for
this and for the use of other drugs would be welcome to
people working in high TB prevalence areas.
The thorny issue of smear-negative TB, a huge headache
for clinicians in countries where diagnostic resources are
lacking, was tackled in a poster looking at using a
‘syndromic approach’, using clinical and simple laboratory
criteria to identify patients with probable TB (Abstract
MoPeB3229).  The model proved robust, confirming the
approach many clinicians are guiltily using – treat patients
with symptoms suggestive of TB and see if they get better,
before breaking out the expensive or invasive diagnostics.
The model may help to formalise this.  The prolific Gavin
Churchyard, from Aurum Research in South Africa,
provided several interesting studies on TB, including one
that showed a 5% incidence of TB among mine workers
after starting ARVs, despite prescreening (MoPeB3213).
Another study from his group showed that oral thrush was
a strong predictive factor for immediate severe HIV-related
illnesses (MoPeC3392), and that perhaps making it a WHO-
4 staging event may be merited.
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CLINICAL PROBLEMS AND OPPORTUNISTIC
ILLNESSES
NEW AND OLD DRUGS, OLD PROBLEMS
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An interesting study showed that HAART decreases the
incidence of opportunistic infections, independent of the
CD4 count, suggesting that the CD4 count may not be as
robust a marker of immune recovery as it is of immune
deficiency (Abstract TuPeC4719). 
A remarkably high level of immune reconstitution
inflammatory syndrome (IRIS) was seen in a cohort of Thai
children commencing ARVs, confirming early anecdotal
reports from paediatricians working in South Africa’s ARV
roll-out (Abstract TuPeB4404). Twenty-four children
developed the syndrome out of 95 starting ARVs.  The
syndrome appeared early (within 3 weeks), and included
cases of mycobacteria, herpes and, curiously, cryptococcus,
which is reported to be rare in children.  Four children died
as a result of the syndrome.  As expected, the lower the CD4
count, the higher the risk of IRIS.
As has been shown in many cohorts, ‘late presenters’ 
(CD4 < 50 cells/µl) are still common even in the developed
world.  A study from the UK showed that these patients
place a huge strain on hospital resources in the first 3
months when compared with people presenting earlier, but
still did very well on ARVs (Abstract MoPeB3356).  The
message for us is obviously to redouble efforts to get
people tested early and referred quickly to an ARV access
point, before they hit the ‘late presenter stage’.
Lymphoma treatment for HIV-infected people is much
better in the era of ARVs  (Abstract ThOrB1403).  Patients
on ARVs showed a dramatic drop in risk of lymphoma.
Those who had lymphomas survived much longer than
those who were not previously given ARVs.  The thorny
question of which drugs to start first (the oncology drugs
or the ARV drugs) and what sequencing of treatment
should be given, remains a thorny everyday question for
clinicians.
A South African study showed increased NVP levels when
given with fluconazole, with an increase in hepatotoxicity
(Abstract WeOrB1239).  This problematic interaction is of
concern to southern African clinicians, where use of
fluconazole is high.  A study comparing amphotericin B
with or without an azole (fluconazole or itraconazole)
found no benefit in terms of cerebrospinal clearance of
cryptococcus or in clinical outcomes (MoPeB3232).
The difficult issue of ARV rationing in Africa was tackled in
Abstract MoOrE1072. A distinction was made between
explicit rationing (e.g. focusing on specified groups such as
skilled workers, students, mothers, households) and the
much more problematic implicit rationing currently in
force (e.g. ‘first come, first served’, queuing, not providing
transport to distant ARV sites). Implicit rationing creates
situations where the elite can queue-jump, undermining
efficiency and equity. The need for public debate was
emphasised — the topic will be comprehensively discussed
in the Lancet later this year.
The prospect of a vaccine seemed about as hopeful as the
cure for old age.  Candidate vaccine corpses have littered
the prevention landscape over the last year, and the news
that we are years and possibly decades from an effective
one was very sobering. Médecines Sans Frontières and a
group of scientists headed by the acerbic Robert Gallo,
called for the scrapping of the huge Thai vaccine trial
currently underway, calling it an expensive flop. Trials of
the diaphragm, with and without vaginal microbicides,
vaccines, and male circumcision  are all interesting but
distant public health interventions.  Treatment of HSV-2 as
an HIV preventive strategy seems very exciting, especially in
the light of recent publications suggesting that herpes may
be the most significant co-factor driving transmission, with
early work starting in South Africa on acyclovir.
The Conference was frustrating, especially if you don’t like
the politics or big crowds.  More frustrating for us were the
surprisingly large number of ‘data-empty’ presentations,
where presenters spoke of their anecdotal experiences
rather than presenting analysis of raw data.  It does seem
that a more rigorous assessment of abstracts is needed, as
the good stuff often seems lost in a sea of mediocre
presentations, leading frustrated observers to write off the
Conference as a waste of time. This would be a pity – this
Conference has fundamentally challenged the way we do
clinical business.  The exciting prospect of simpler and safer
ARV therapy seems only a few years away.  The next
Conference is in 2006 in Toronto.  It may not have the buzz
of Bangkok, but it will certainly attract the AIDS conference
crowd in droves.  Here’s hoping we won’t be discussing NVP
this time.
All abstracts, and selected webcasts, are freely available at
the IAS website, http://www.ias.se/
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